We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 195

Patent damage awards studied
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

Legal analytics firm Lex Machina has issued a "Patent Litigation Damages Report" that analyzes patent litigation damages awarded in U.S. district


French company prevails in dispute with FDA over drug-classification ruling
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements


Genescience pleads guilty to charges of selling human growth hormones in U.S.
  • Shook Hardy & Bacon LLP
  • USA
  • October 21 2010

GeneScience Pharmaceutical Co, Ltd and its CEO have pleaded guilty to selling Jintropin, a human growth hormone used to build muscle, without the approval of the Food and Drug Administration


Eighth Circuit says pleadings can be filed under seal, but needs more justification
  • Shook Hardy & Bacon LLP
  • USA
  • February 21 2013

The Eighth Circuit Court of Appeals has determined that a federal district court did not abuse its discretion in sealing an antitrust complaint


Compounding pharmacy enters consent decree with FDA
  • Shook Hardy & Bacon LLP
  • USA
  • July 11 2013

As part of its efforts to ensure the safety of compounded pharmaceuticals since a Hepatitis A outbreak was traced in 2012 to a drug compounding


Federal Circuit reminds litigants to cross-appeal patent invalidity claim
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

The Federal Circuit Court of Appeals, in the context of patents on improvements to electronic animal collars, has in large part affirmed a lower


Court orders dispute over 23andMe DNA test kits to arbitration
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

A multidistrict litigation court in California has ordered false-advertising, class-action claims filed against personal genetics company 23andMe to


Consumer-fraud class action filed against 23andme after FDA action
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

Citing the Food and Drug Administration's (FDA's) November 22, 2013, warning letter, a California resident has filed a putative class action against


Federal court denies HHS motion to seal documents in medical-device whistleblower
  • Shook Hardy & Bacon LLP
  • USA
  • January 10 2013

A federal court in the District of Columbia has denied the government's request to seal an exhibit in Freedom of Information Act litigation over records


Myriad Genetics calls on Scotus to reject petition from ruling finding DNA molecules patent-eligible
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

According to Myriad Genetics, Inc., the U.S. Supreme Court should not grant review in Association for Molecular Pathology v. Myriad Genetics, Inc. Details about the Federal Circuit Court of Appeals decision on remand from the lawsuit’s previous sojourn before the U.S. Supreme Court appear in Issue 41 of this Bulletin